Danish Allergy vaccine company ALK-Abelló (which now refers to itself simply as ALK) has announced positive results of a Phase II/III clinical study of its tablet vaccine against house dust mite allergy. The news was posted on the company's website yesterday.
According to the company, the study showed a 50% reduction in the use of asthma medicine and demonstrated that the tablet vaccine is well tolerated and has a good safety profile.
Last year ALK launched the world's first registered tablet-based allergy vaccine, Grazax, for grass pollen allergy. The treatment for house dust mite allergy is the next tablet vaccine in ALK's product pipeline.
After grass, house dust mite allergy is the most common type of allergy worldwide.
The placebo-controlled study included 604 adolescent and adult patients and was conducted over 18 months at 80 clinical centres in eight European countries. ALK will now continue with further clinical studies with a view to obtaining a future European approval of the product. On the North American markets, ALK has licensed the product rights to its US partner, Schering-Plough.
Headquartered in Hørsholm north of Copenhagen, ALK has been active in allergy immunotherapy since 1923. The company's product pipeline contains tablet-based treatments, based on natural allergens, against grass and house dust mites. ALK employs more than 1,200 people and has subsidiaries, production facilities and distributors throughout the world. The company is listed on the OMX Nordic Exchange Copenhagen.